These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24445718)

  • 1. ACP Journal Club. Review: in type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis.
    Morey-Vargas OL; Montori VM
    Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445718
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
    Schectman J
    Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
    [No Abstract]   [Full Text] [Related]  

  • 3. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

  • 4. GLP-1-based therapies: the dilemma of uncertainty.
    Spranger J; Gundert-Remy U; Stammschulte T
    Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitis/pancreatic cancer.
    Shirakawa J; Terauchi Y
    J Diabetes Investig; 2020 Jul; 11(4):789-791. PubMed ID: 31774618
    [No Abstract]   [Full Text] [Related]  

  • 6. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors.
    Lee M; Sun J; Han M; Cho Y; Lee JY; Nam CM; Kang ES
    Diabetes Care; 2019 Nov; 42(11):2057-2064. PubMed ID: 31431452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):48-56. PubMed ID: 23837679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
    de Heer J; Göke B
    Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
    Nauck MA; Meier JJ; Schmidt WE
    Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
    [No Abstract]   [Full Text] [Related]  

  • 10. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
    Raz I; Bhatt DL; Hirshberg B; Mosenzon O; Scirica BM; Umez-Eronini A; Im K; Stahre C; Buskila A; Iqbal N; Greenberger N; Lerch MM
    Diabetes Care; 2014 Sep; 37(9):2435-41. PubMed ID: 24914244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of incretin based drug treatments for type 2 diabetes.
    Bolen SD; Maruthur NM
    BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
    [No Abstract]   [Full Text] [Related]  

  • 12. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 13. The safety of incretin based drugs.
    Montori VM
    BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
    [No Abstract]   [Full Text] [Related]  

  • 14. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Smits MM; Muskiet MH; Tonneijck L; van Raalte DH
    Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
    Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232
    [No Abstract]   [Full Text] [Related]  

  • 16. Preying on the pancreas? Scientists debate whether newer diabetes medications do harm.
    Berg EG
    Diabetes Forecast; 2013 Oct; 66(10):26, 28, 30-1. PubMed ID: 24224353
    [No Abstract]   [Full Text] [Related]  

  • 17. Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study.
    Lai SW; Lin CL; Liao KF
    Mayo Clin Proc; 2018 Dec; 93(12):1874-1876. PubMed ID: 30522598
    [No Abstract]   [Full Text] [Related]  

  • 18. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
    Roshanov PS; Dennis BB
    Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute pancreatitis with dipeptidyl peptidase-4 (DPP4) inhibitor or fulminant type 1 diabetes?
    Amouyal C; Levy P; Andreelli F; Hartemann A
    Diabetes Metab; 2018 Feb; 44(1):95-96. PubMed ID: 28483292
    [No Abstract]   [Full Text] [Related]  

  • 20. Vildagliptin-induced acute pancreatitis without enzyme elevation.
    Mungan Z; Attila T; Ünal Kabaoğlu Z; Vural M
    Turk J Gastroenterol; 2017 Nov; 28(6):514-517. PubMed ID: 29086719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.